Q2 EPS Estimates for Core Scientific Raised by HC Wainwright

Core Scientific, Inc. (NASDAQ:CORZ) – Equities researchers at HC Wainwright boosted their Q2 2025 earnings per share estimates for Core Scientific in a research note issued on Thursday, May 8th. HC Wainwright analyst K. Dede now forecasts that the company will post earnings of ($0.09) per share for the quarter, up from their prior forecast of ($0.10). HC Wainwright currently has a “Buy” rating and a $17.00 target price on the stock. The consensus estimate for Core Scientific’s current full-year earnings is $0.52 per share. HC Wainwright also issued estimates for Core Scientific’s Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.02 EPS and FY2025 earnings at $0.25 EPS.

CORZ has been the subject of several other research reports. Cantor Fitzgerald reduced their price target on shares of Core Scientific from $24.00 to $21.00 and set an “overweight” rating for the company in a research report on Thursday, February 27th. Canaccord Genuity Group restated a “buy” rating and issued a $17.00 target price on shares of Core Scientific in a report on Friday. Keefe, Bruyette & Woods started coverage on Core Scientific in a research report on Monday, January 27th. They issued an “outperform” rating and a $22.00 target price for the company. Craig Hallum assumed coverage on Core Scientific in a research report on Tuesday, January 21st. They set a “buy” rating and a $24.00 price target on the stock. Finally, Needham & Company LLC cut their target price on shares of Core Scientific from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. Fifteen analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $19.07.

Core Scientific Price Performance

Core Scientific stock opened at $9.32 on Monday. Core Scientific has a fifty-two week low of $3.46 and a fifty-two week high of $18.63. The firm’s 50 day simple moving average is $7.92 and its 200-day simple moving average is $12.06. The company has a market cap of $2.75 billion, a P/E ratio of -1.72 and a beta of 6.66.

Core Scientific (NASDAQ:CORZ) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.02. The company had revenue of $79.53 million for the quarter, compared to analyst estimates of $92.04 million. During the same quarter in the previous year, the firm posted $0.78 EPS. Core Scientific’s quarterly revenue was down 55.6% on a year-over-year basis.

Institutional Investors Weigh In On Core Scientific

A number of hedge funds have recently bought and sold shares of the company. Xponance Inc. increased its stake in shares of Core Scientific by 7.9% in the fourth quarter. Xponance Inc. now owns 12,800 shares of the company’s stock worth $180,000 after purchasing an additional 937 shares during the period. Summit Investment Advisors Inc. grew its holdings in Core Scientific by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 18,658 shares of the company’s stock valued at $262,000 after buying an additional 1,185 shares during the last quarter. SBI Securities Co. Ltd. increased its position in Core Scientific by 17.8% in the 1st quarter. SBI Securities Co. Ltd. now owns 10,391 shares of the company’s stock worth $75,000 after buying an additional 1,567 shares during the period. US Bancorp DE lifted its holdings in shares of Core Scientific by 23.7% during the first quarter. US Bancorp DE now owns 8,682 shares of the company’s stock worth $63,000 after buying an additional 1,663 shares during the last quarter. Finally, Wellington Shields & Co. LLC acquired a new position in shares of Core Scientific during the fourth quarter worth approximately $26,000.

Insider Buying and Selling

In related news, Director Jordan Levy bought 62,500 shares of the firm’s stock in a transaction on Thursday, March 6th. The stock was purchased at an average price of $8.01 per share, with a total value of $500,625.00. Following the completion of the transaction, the director now directly owns 306,887 shares of the company’s stock, valued at $2,458,164.87. This trade represents a 25.57% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Todd A. Becker sold 134,250 shares of Core Scientific stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $10.75, for a total transaction of $1,443,187.50. Following the completion of the transaction, the director now directly owns 195,687 shares in the company, valued at approximately $2,103,635.25. This represents a 40.69% decrease in their position. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by corporate insiders.

Core Scientific Company Profile

Core Scientific, Inc provides digital asset mining services in North America. It operates through two segments, Mining and Hosting. The company offers blockchain infrastructure, software solutions, and services; and operates data center mining facilities. It also mines digital assets for its own account; and provides hosting services for other large bitcoin miners, which include deployment, monitoring, trouble shooting, optimization, and maintenance of its customers' digital asset mining equipment.